Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Laura V. Stampleman"'
Autor:
Omar Nadeem, Robert Redd, Laura V. Stampleman, Jeffrey V. Matous, Andrew J. Yee, Jeffrey A. Zonder, Andrew Kin, Jacalyn Rosenblatt, Mark Bustoros, MD, Julia Prescott, Alexandra Savell, Kathleen Guimond, Erin Frey, Rachel Styles, Adrienne Bielawski, Cody J Boehner, Nang Kham Su, Multiple Myeloma Research Foundation Multiple Myeloma Research Foundation, The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society, BCRP Blood Cancer Research Partnership, Adam S Sperling, Giada Bianchi, Jacob P. Laubach, Jorge J. Castillo, Nikhil C. Munshi, Kenneth C. Anderson, Paul G. Richardson, Lorenzo Trippa, Irene M. Ghobrial
Publikováno v:
Blood. 134:1898-1898
Introduction: Daratumumab (DARA) is an anti-CD38 monoclonal antibody that is approved for use in patients with newly diagnosed and relapsed multiple myeloma (MM). We hypothesized that early therapeutic intervention with DARA in patients with high-ris
Autor:
James R. Berenson, Jennifer To, Tanya M. Spektor, Daisy Martinez, Armando J. Sanchez, Carley Turner, Regina Swift, Benjamin Eades, Gary Schwartz, Shahrooz Eshaghian, Laura V. Stampleman, Robert A. Moss, Youram Nassir, Ravindranath Patel, Alberto Bessudo, Daniel Greenwald, Ralph V. Boccia, Stephen Lim, Robert Vescio
Publikováno v:
Blood. 134:1903-1903
Introduction Ruxolitinib (RUX) is an FDA-approved oral, selective inhibitor of Janus kinase (JAK) 1/2 for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea or intermediate or high